Seattle, WA Clinical Trials Report — July 2026

Seattle participants should act quickly if they match a study nearing its enrollment deadline: 52 recruiting trials are expected to close within the next 90 days, including 11 that accept healthy volunteers. Seattle remains a major Washington research center, with 1,242 recruiting trials across 346 facilities.

New openings slowed in July. Seattle added 17 trials this month, compared with 30 in June and 20 in May. Even with fewer new launches, several large Phase 3 studies from AstraZeneca and Bristol-Myers Squibb opened locally, alongside pediatric infection research, teen vaping research, and a University of Washington whole-genome sequencing study.

Closing-soon studies create the most immediate opportunities

Enrollment can end before a projected closing date if a study reaches its participant target. People with the following conditions should contact research teams promptly and confirm that Seattle sites are still enrolling:

• Amputation (2 trials)
• Cystic fibrosis (2 trials)
• Hematopoietic and lymphatic system neoplasms (2 trials)
• Advanced solid tumors (2 trials)
• Refractory hematologic malignancies (2 trials)
• Head and neck squamous cell carcinoma (2 trials)
• Ann Arbor stage III follicular lymphoma (1 trial)
• Advanced melanoma (1 trial)
• Adolescent behavior (1 trial)
• AML with mutated NPM1 (1 trial)

Healthy volunteers have 11 closing-soon options among the 52 studies nearing their enrollment window. Across Seattle overall, 114 recruiting trials accept healthy volunteers. Screening may involve age requirements, medication restrictions, health checks, laboratory testing, or multiple visits, so interested volunteers should apply early rather than wait for the listed closing date.

Large new studies include AstraZeneca and Bristol-Myers Squibb trials

July’s new-trial mix includes 9 drug studies, 5 classified as other, 4 biological studies, 3 procedures, and one behavioral and one genetic study. University of Washington sponsors 6 new studies, Fred Hutchinson Cancer Center sponsors 3, and AstraZeneca sponsors 2. Overall, 12 new trials are categorized as academic or other-sponsored studies and 5 as industry-sponsored.

• NCT07720284 is AstraZeneca’s Phase 3 study of dato-DXd plus rilvegostomig versus standard care for adults with high-risk muscle-invasive urothelial cancer after surgery. The planned enrollment is 915 participants, and treatment may continue for up to about 12 months.
• NCT07680790 is Bristol-Myers Squibb’s Phase 3 IZABRIGHT-Lung02 study. It compares izalontamab brengitecan with osimertinib against osimertinib alone or osimertinib plus platinum-based chemotherapy in previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer. Planned enrollment is 850 participants.
• NCT07730814 is a Phase 4, 1,100-participant study sponsored by Nader Shaikh that compares available treatments for acute otitis media in children, including antibiotic approaches.
• NCT07732699 is a related Phase 4, 1,100-participant pediatric study of treatments for acute sinusitis, also sponsored by Nader Shaikh.
• NCT07739706, sponsored by Fred Hutchinson Cancer Center, compares the QuitQuest smartphone application with the National Cancer Institute’s SmokefreeTeenQuitVaping app to help teens stop vaping. The study plans to enroll 1,072 participants.
• NCT07718971, sponsored by the University of Washington, studies whether whole-genome sequencing can identify diagnoses and guide care for adults whose conditions have not previously been diagnosed. Planned enrollment is 1,000 participants.

Newly represented conditions include acute sinusitis, aplastic anemias, autoimmune diseases, bone marrow failure syndromes, brain tumors, brainstem glioma, adult cancers, and multiple stages of breast cancer. Five July studies include children, one is female-only, one is male-only, and 11 include older adults.

Seattle’s leading research facilities

The University of Washington is the city’s largest listed research site, followed by Seattle Children’s Hospital and Fred Hutchinson Cancer Center. Together, these institutions give Seattle strong coverage in oncology, pediatric medicine, genetics, infectious disease, and other specialties. Cancer patients may find particularly dense options through Fred Hutch and its UW cancer consortium, while families should look first at Seattle Children’s for pediatric studies.

• University of Washington (179 trials)
• Seattle Children’s Hospital (167 trials)
• Fred Hutchinson Cancer Center (139 trials)
• Fred Hutch/UW Cancer Consortium (86 trials)
• Swedish Medical Center-First Hill (72 trials)
• University of Washington Medical Center (48 trials)
• Swedish Medical Center-Ballard Campus (42 trials)
• Swedish Medical Center-Cherry Hill (42 trials)
• University of Washington Medical Center - Montlake (42 trials)
• Swedish Cancer Institute (41 trials)
• Virginia Mason Medical Center (38 trials)
• Swedish Medical Center (38 trials)

People considering a study should confirm the exact location with the trial team because a sponsor may list several affiliated facilities separately. The number of recruiting trials at a facility also does not guarantee that every study is accepting new participants on a given day.

Nearby Washington alternatives

Participants who can travel beyond Seattle can also search nearby Washington locations. Spokane has 3 recruiting trials, while Burien, Joint Base Lewis-McChord, and Tacoma each have 1. These smaller listings may be useful when a Seattle study has restrictive eligibility or has already filled its local enrollment slots.

Seattle’s six-month pattern has fluctuated: 28 new trials opened in February, followed by 18 in March, 16 in April, 20 in May, 30 in June, and 17 in July. With 114 healthy-volunteer studies active and several high-enrollment Phase 3 programs newly available, prospective participants should monitor local listings and contact sites early as the summer pipeline develops.